{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:42:28Z","timestamp":1773909748056,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Real-world studies permit inclusion of a more diverse patient population and provide more information on the effectiveness of treatments used in routine clinical practice. This prospective, multicenter, observational study investigated the effectiveness and safety of ixazomib plus lenalidomide and dexamethasone (IRd) in 295 patients with relapsed\/refractory multiple myeloma (RRMM) in routine clinical practice in Japan. Patients had a median age of 74\u00a0years, 80.0% were aged\u2009\u2265\u200965\u00a0years, 42.0% had received\u2009\u2265\u20093 lines of prior treatment, and 28.5% were \u201cfrail\u201d according to the International Myeloma Working Group frailty score. After a median follow-up of 25.0\u00a0months, median progression-free survival (PFS) was 15.3 (95% CI 12.4\u201319.5) months, while median overall survival was not reached. The overall response rate was 53.9%, and 31.5% of patients had a very good partial response or better. In the subgroup analysis, median PFS was better in patients with 1 versus 2 or\u2009\u2265\u20093 lines of prior treatment (29.0 vs 19.2 or 6.9\u00a0months) and paraprotein versus clinical relapse (16.0 vs 7.9\u00a0months), but median PFS was not notably affected by frailty score or age group. Dose adjustment was more frequent among patients aged\u2009&gt;\u200975\u00a0years, especially early after IRd treatment initiation. Treatment-emergent adverse events (TEAEs) of any grade occurred in 84.4% of patients and 24.7% of patients discontinued treatment due to TEAEs; no new safety concerns were found. These findings suggest that oral IRd triplet regimen is an effective and tolerable treatment option for RRMM patients in real-world settings outside of clinical trials.<\/jats:p><jats:p>ClinicalTrials.gov identifier: NCT03433001; Date of registration: 14 February 2018.<\/jats:p>","DOI":"10.1007\/s00277-023-05428-7","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T05:01:40Z","timestamp":1694408500000},"page":"475-488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in Japan"],"prefix":"10.1007","volume":"103","author":[{"given":"Yuichi","family":"Horigome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Iino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoriko","family":"Harazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiga","family":"Kuroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiwamu","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-960X","authenticated-orcid":false,"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"5428_CR1","unstructured":"World Health Organization (2020) Global Cancer Observatory: Cancer Today (Japan). https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/392-japan-fact-sheets.pdf. Accessed 08 June 2022"},{"key":"5428_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/jjco\/hyab178","volume":"52","author":"N Suzuki","year":"2022","unstructured":"Suzuki N, Okuyama T, Akechi T, Kusumoto S, Ri M, Inagaki A et al (2022) Symptoms and health-related quality of life in patients with newly diagnosed multiple myeloma: a multicenter prospective cohort study. Jpn J Clin Oncol 52:163\u20139. https:\/\/doi.org\/10.1093\/jjco\/hyab178","journal-title":"Jpn J Clin Oncol"},{"key":"5428_CR3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/jjco\/hyac111","volume":"52","author":"T Suzuki","year":"2022","unstructured":"Suzuki T, Maruyama D, Iida S, Nagai H (2022) Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan. Jpn J Clin Oncol 52:966\u201374. https:\/\/doi.org\/10.1093\/jjco\/hyac111","journal-title":"Jpn J Clin Oncol"},{"key":"5428_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA et al (2018) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 32:252\u201362. https:\/\/doi.org\/10.1038\/leu.2017.329","journal-title":"Leukemia"},{"key":"5428_CR5","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e46. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"5428_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/13696998.2019.1686870","volume":"23","author":"S Uno","year":"2020","unstructured":"Uno S, Goto R, Suzuki K, Iwasaki K, Takeshima T, Ohtsu T (2020) Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database. J Med Econ 23:166\u201373. https:\/\/doi.org\/10.1080\/13696998.2019.1686870","journal-title":"J Med Econ"},{"key":"5428_CR7","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.Can-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A et al (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70:1970\u201380. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-2766","journal-title":"Cancer Res"},{"key":"5428_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/DDDT.S93602","volume":"10","author":"B Muz","year":"2016","unstructured":"Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK (2016) Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther 10:217\u201326. https:\/\/doi.org\/10.2147\/DDDT.S93602","journal-title":"Drug Des Devel Ther"},{"key":"5428_CR9","unstructured":"Takeda (2017) Takeda obtains new drug application approval for NINLARO\u00ae capsules for the treatment of multiple myeloma in Japan. http:\/\/www.takeda.com\/newsroom\/newsreleases\/2017\/20170330_ninlaro\/. Accessed 09 May 2022."},{"key":"5428_CR10","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374:1621\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1516282","journal-title":"N Engl J Med"},{"key":"5428_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP et al (2018) Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J 8:109. https:\/\/doi.org\/10.1038\/s41408-018-0141-0","journal-title":"Blood Cancer J"},{"key":"5428_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","volume":"20","author":"A Chari","year":"2020","unstructured":"Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A et al (2020) Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 20:8-17.e6. https:\/\/doi.org\/10.1016\/j.clml.2019.09.625","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5428_CR13","unstructured":"Pharmaceuticals and Medical Devices Agency (2019) Revlimid: Package insert (in Japanese). https:\/\/www.info.pmda.go.jp\/go\/pack\/4291024M1024_2_01\/. Accessed 10 June 2022."},{"key":"5428_CR14","unstructured":"Pharmaceuticals and Medical Devices Agency (2021) Ninlaro: Package insert (in Japanese). https:\/\/www.info.pmda.go.jp\/downfiles\/guide\/ph\/400256_4291049M1024_1_01G.pdf. Accessed 10 June 2022."},{"key":"5428_CR15","unstructured":"Pharmaceuticals and Medical Devices Agency (2022) Decadron: Package insert (in Japanese). https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00062800.pdf. Accessed 10 June 2022."},{"key":"5428_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I et al (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373:621\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1505654","journal-title":"N Engl J Med"},{"key":"5428_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2014","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A et al (2014) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372:142\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1411321","journal-title":"N Engl J Med"},{"key":"5428_CR18","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1607751","journal-title":"N Engl J Med"},{"key":"5428_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12185-019-02615-z","volume":"109","author":"H Takamatsu","year":"2019","unstructured":"Takamatsu H, Yoroidaka T, Fujisawa M, Kobori K, Hanawa M, Yamashita T et al (2019) Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol 109:377\u201381. https:\/\/doi.org\/10.1007\/s12185-019-02615-z","journal-title":"Int J Hematol"},{"key":"5428_CR20","doi-asserted-by":"publisher","first-page":"S247","DOI":"10.1016\/j.clml.2018.07.146","volume":"18","author":"C Costello","year":"2018","unstructured":"Costello C, Boccadoro M, Usmani S, Chari A, Rifkin R, Abonour R et al (2018) A global treatment standard in multiple myeloma (MM) remains elusive despite advances in care over 15 years: first results from INSIGHT MM, the largest global prospective, observational MM study. Clin Lymphoma Myeloma Leuk 18:S247\u2013S8. https:\/\/doi.org\/10.1016\/j.clml.2018.07.146","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5428_CR21","doi-asserted-by":"publisher","unstructured":"Ludwig H, Terpos E, Mateos M-V, Boccadoro M, Kishore B, Ramasamy K, et al (2020) Effectiveness and safety of ixazomib-based therapy in relapsed\/refractory multiple myeloma (RRMM) patients (pts) treated outside the clinical trial setting via an Early Access Program (EAP) in Europe: second interim analysis of the \u2018Use Via Early Access to Ixazomib\u2019 (UVEA-IXA) study. Blood 136:42-4. https:\/\/doi.org\/10.1182\/blood-2020-136519","DOI":"10.1182\/blood-2020-136519"},{"key":"5428_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12885-020-07732-1","volume":"21","author":"J Minarik","year":"2021","unstructured":"Minarik J, Pika T, Radocha J, Jungova A, Straub J, Jelinek T et al (2021) Survival benefit of ixazomib, lenalidomide and dexamethasone (IRd) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer 21:73. https:\/\/doi.org\/10.1186\/s12885-020-07732-1","journal-title":"BMC Cancer"},{"key":"5428_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-021-04663-0","volume":"101","author":"J Sokol","year":"2022","unstructured":"Sokol J, Guman T, Chudej J, Hlebaskova M, Stecova N, Valekova L et al (2022) Ixazomib, lenalidomide, and dexamethasone combination in \u201creal-world\u201d clinical practice in patients with relapsed\/refractory multiple myeloma. Ann Hematol 101:81\u20139. https:\/\/doi.org\/10.1007\/s00277-021-04663-0","journal-title":"Ann Hematol"},{"key":"5428_CR24","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2018-99-112846","volume":"132","author":"SZ Usmani","year":"2018","unstructured":"Usmani SZ, Hungria VTM, Leleu X, Lee HC, Davies FE, Costello CL et al (2018) Transplant status does not impact the selection of induction regimens for newly diagnosed multiple myeloma (NDMM) patients (pts) in the Insight MM prospective, observational study. Blood 132:3289. https:\/\/doi.org\/10.1182\/blood-2018-99-112846","journal-title":"Blood"},{"key":"5428_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-133807","volume":"136","author":"L Clement-Filliatre","year":"2020","unstructured":"Clement-Filliatre L, Benboubker L, Stoppa A-M, Rodon P, Laribi K, Vincent L et al (2020) Real-life-setting effectiveness of ixazomib in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: the Remix study. Blood 136:25\u20136. https:\/\/doi.org\/10.1182\/blood-2020-133807","journal-title":"Blood"},{"key":"5428_CR26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00277-020-03981-z","volume":"99","author":"E Terpos","year":"2020","unstructured":"Terpos E, Ramasamy K, Maouche N, Minarik J, Ntanasis-Stathopoulos I, Katodritou E et al (2020) Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma. Ann Hematol 99:1049\u201361. https:\/\/doi.org\/10.1007\/s00277-020-03981-z","journal-title":"Ann Hematol"},{"key":"5428_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/17474086.2020.1729734","volume":"13","author":"A Chari","year":"2020","unstructured":"Chari A, Richardson PG, Romanus D, Dimopoulos MA, Sonneveld P, Terpos E et al (2020) Real-world outcomes and factors impacting treatment choice in relapsed and\/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Rev Hematol 13:421\u201333. https:\/\/doi.org\/10.1080\/17474086.2020.1729734","journal-title":"Expert Rev Hematol"},{"key":"5428_CR28","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00277-021-04534-8","volume":"100","author":"F Davies","year":"2021","unstructured":"Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R et al (2021) Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed\/refractory multiple myeloma (RRMM) in the US. Ann Hematol 100:2325\u201337. https:\/\/doi.org\/10.1007\/s00277-021-04534-8","journal-title":"Ann Hematol"},{"key":"5428_CR29","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2217\/fon-2020-1225","volume":"17","author":"R H\u00e1jek","year":"2021","unstructured":"H\u00e1jek R, Mina\u0159\u00edk J, Straub J, Pour L, Jungova A, Berdeja JG et al (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed\/refractory multiple myeloma. Future Oncol 17:2499\u2013512. https:\/\/doi.org\/10.2217\/fon-2020-1225","journal-title":"Future Oncol"},{"key":"5428_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12185-022-03479-6","volume":"117","author":"JH Lee","year":"2023","unstructured":"Lee JH, Kim SH, Kim HR, Min CK, Lee JJ, Shin HJ et al (2023) Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and\/or refractory multiple myeloma. Int J Hematol 117:225\u201335. https:\/\/doi.org\/10.1007\/s12185-022-03479-6","journal-title":"Int J Hematol"},{"key":"5428_CR31","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2217\/fon-2019-0013","volume":"15","author":"C Costello","year":"2019","unstructured":"Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM et al (2019) INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncol 15:1411\u201328. https:\/\/doi.org\/10.2217\/fon-2019-0013","journal-title":"Future Oncol"},{"key":"5428_CR32","doi-asserted-by":"publisher","unstructured":"Minarik J, Radocha J, Jungova A, Straub J, Jelinek T, Pika T, et al (2022) Ixazomib, lenalidomide and dexamethasone in relapsed and refractory multiple myeloma in routine clinical practice: extended follow-up analysis and the results of subsequent therapy. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14205165","DOI":"10.3390\/cancers14205165"},{"key":"5428_CR33","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2147\/ott.S95818","volume":"9","author":"Y Hu","year":"2016","unstructured":"Hu Y, Chen W, Chen S, Huang Z (2016) Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization. Onco Targets Ther 9:1145\u20139. https:\/\/doi.org\/10.2147\/ott.S95818","journal-title":"Onco Targets Ther"},{"key":"5428_CR34","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L et al (2017) Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients. Blood 130:2610\u20138. https:\/\/doi.org\/10.1182\/blood-2017-06-791228","journal-title":"Blood"},{"key":"5428_CR35","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/jco.21.00972","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M et al (2021) Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 39:2430\u201342. https:\/\/doi.org\/10.1200\/jco.21.00972","journal-title":"J Clin Oncol"},{"key":"5428_CR36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s10147-021-02030-7","volume":"27","author":"S Iida","year":"2022","unstructured":"Iida S, Izumi T, Komeno T, Terui Y, Chou T, Ikeda T et al (2022) A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and\/or refractory multiple myeloma. Int J Clin Oncol 27:224\u201333. https:\/\/doi.org\/10.1007\/s10147-021-02030-7","journal-title":"Int J Clin Oncol"},{"key":"5428_CR37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/asheducation-2017.1.212","volume":"2017","author":"H Ludwig","year":"2017","unstructured":"Ludwig H, Zojer N (2017) Fixed duration vs continuous therapy in multiple myeloma. Hematol Am Soc Hematol Educ Program 2017:212\u201322. https:\/\/doi.org\/10.1182\/asheducation-2017.1.212","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"5428_CR38","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/ppa.S106629","volume":"10","author":"D Eek","year":"2016","unstructured":"Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R et al (2016) Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence 10:1609\u201321. https:\/\/doi.org\/10.2147\/ppa.S106629","journal-title":"Patient Prefer Adherence"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05428-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05428-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05428-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T07:03:55Z","timestamp":1705647835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05428-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["5428"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05428-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committees of Nagoya City University Graduate School of Medical Sciences (Approval No.: 50\u201317-0002, 12 April 2018) and other participating institutes. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects, and complied with all applicable laws and regulations, including data privacy laws, and guidelines and regulations on conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients prior to any study procedures being undertaken.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Yuichi Horigome has received honoraria for lectures and advisory board fees from Janssen. Takahiro Kobayashi has received speaker fees from Ono Pharmaceutical, Bristol-Myers Squibb, Takeda, Fujimoto, Janssen, and Sanofi. Hiroshi Handa has received research grants from Takeda, Bristol-Myers Squibb, and Kyowa Kirin; consulting fees from Takeda, Janssen, and Bristol-Myers Squibb; lecture fees from Takeda, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, and Sanofi; meeting fees, medical writing fees, and the article processing charge from Takeda; and counselling fees from Japanese Society of Myeloma. Masahiro Abe has received honoraria from Takeda, Bristol-Myers Squibb, Janssen, Sanofi, Ono Pharmaceutical, and Daiichi Sankyo and is the President of the Japanese Society of Myeloma. Tadao Ishida has received grants from Janssen and Bristol-Myers Squibb; and honoraria from Ono Pharmaceutical, Janssen, Bristol-Myers Squibb, Takeda, and Sanofi. Shigeki Ito has received clinical trial contracts from Bristol-Myers Squibb; and lecture fees from Bristol-Myers Squibb and Takeda. Hiromi Iwasaki has received grants from Kyowa Kirin; and honoraria from Takeda, Daiichi Sankyo, SymBio, LSI Medience, AbbVie, Ono Pharmaceutical, Chugai, Janssen, Sanofi, AstraZeneca, and Kyowa Kirin. Junya Kuroda has received grants from Kyowa Kirin, Chugai, Daiichi Sankyo, Ono Pharmaceutical, Eisai, Taiho, Sumitomo, Shionogi, and Bristol-Myers Squibb; honoraria from Ono Pharmaceutical, Sanofi, Bristol-Myers Squibb, and Janssen; advisory board fees from Janssen, Bristol-Myers Squibb, Asahikasei Pharma, and Pfizer; and fees for other services from Bristol-Myers Squibb and Taiho. Hirohiko Shibayama has received fees for manuscript writing and for attending meetings from Takeda; grants from Ono Pharmaceutical and Bristol-Myers Squibb; consulting fees from Takeda, Fujimoto, Eisai, AstraZeneca, Janssen, AbbVie, and Sanofi; and honoraria from Takeda, Chugai, AstraZeneca, Ono Pharmaceutical, Janssen, and Sanofi. Kazutaka Sunami has received research funding from Ono Pharmaceutical, Celgene, AbbVie, Takeda, Sanofi, Bristol-Myers Squibb, GlaxoSmithKline, Chugai, Otsuka, and Janssen; and honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Takeda, and Sanofi. Hiroyuki Takamatsu has received grants from Bristol-Myers Squibb; consulting fees from SRL; and honoraria from Janssen, Ono Pharmaceutical, Sanofi, and Bristol-Myers Squibb. Hideto Tamura has received lecture fees from Sanofi, Bristol-Myers Squibb, Ono Pharmaceutical, Janssen, Chugai, and Takeda. Toshiaki Hayashi has received speaker fees from Takeda, Bristol-Myers Squibb, Ono Pharmaceutical, Sanofi, and Fujimoto. Kiwamu Akagi has received lecture fees from Merck Sharp & Dohme, Chugai, AstraZeneca, Bristol-Myers Squibb, Mochida, Taiho, and Roche; and advisory board fees from Takeda. Takahiro Maeda has received grants from Japan Society for the Promotion of Science, the Japanese Society of Hematology, Kyowa Kirin, and Takeda; and honoraria from Kyowa Kirin, Otsuka, Novartis, Sumitomo, Chugai, Takeda, Astellas Pharma Inc., and AbbVie. Tomohiro Shinozaki has received lecture fees from Santen Pharmaceutical, Novartis, and CMIC Holdings Co., Ltd.; and fees for attending meetings from Takeda. Shinsuke Iida has received grants from Takeda, Sanofi, Janssen, AbbVie, Novartis, Amgen, GlaxoSmithKline, Bristol-Myers Squibb, Daiichi Sankyo, Ono Pharmaceutical, Chugai, Otsuka, Celgene, and Alexion; consulting fees from Takeda, Janssen, Pfizer, AbbVie, Sanofi, Otsuka, GlaxoSmithKline, Regeneron, Bristol-Myers Squibb, and Novartis; and lecture fees from Janssen, Takeda, Bristol-Myers Squibb, Sanofi, and Ono Pharmaceutical. Takahiro Yoshida and Ikuo Mori are employees of Takeda Pharmaceutical Co. Ltd. Masaki Iino, Yoriko Harazaki, Yasushi Hiramatsu, Taiga Kuroi, Kazuki Tanimoto, and Kosei Matsue have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}